A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with
Platinum‐Sensitive
Ovarian Cancer
Authors
Keywords
-
Journal
ONCOLOGIST
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-12-09
DOI
10.1002/onco.13630
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer
- (2020) Bradley J. Monk et al. GYNECOLOGIC ONCOLOGY
- Low rates of BRCA1 and BRCA2 testing for patients with ovarian cancer in ASCO's CancerLinQ, a real-world database.
- (2020) Summer Dewdney et al. JOURNAL OF CLINICAL ONCOLOGY
- Patterns and adoption of BRCA testing in ovarian cancer in the real world: Observations from Flatiron Health
- (2020) L. Meyer et al. GYNECOLOGIC ONCOLOGY
- Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer
- (2019) Ignacio Romero et al. ANTI-CANCER DRUGS
- Treatment of recurrent epithelial ovarian cancer
- (2019) Sandro Pignata et al. CANCER
- Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
- (2018) Ingo B. Runnebaum et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Optimizing treatment in recurrent epithelial ovarian cancer
- (2017) Giacomo Corrado et al. Expert Review of Anticancer Therapy
- Trabectedin as a chemotherapy option for patients with BRCA deficiency
- (2016) Bradley J. Monk et al. CANCER TREATMENT REVIEWS
- Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†
- (2015) B. J. Monk et al. ANNALS OF ONCOLOGY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Unique features of trabectedin mechanism of action
- (2015) Annette K. Larsen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer
- (2015) Maria Ornella Nicoletto et al. TUMORI
- Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer
- (2015) Maria Ornella Nicoletto et al. TUMORI JOURNAL
- New developments in the treatment of ovarian cancer--future perspectives
- (2013) J. Lopez et al. ANNALS OF ONCOLOGY
- Trabectedin
- (2013) Paola Allavena et al. OncoImmunology
- Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
- (2012) Bradley J. Monk et al. EUROPEAN JOURNAL OF CANCER
- Evaluating New Regimens in Recurrent Ovarian Cancer: How Much Evidence Is Good Enough?
- (2010) Stephen A. Cannistra JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- A Review of Trabectedin (ET-743): A Unique Mechanism of Action
- (2010) Maurizio D'Incalci et al. MOLECULAR CANCER THERAPEUTICS
- Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs
- (2009) Philipp Harter et al. Expert Review of Anticancer Therapy
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now